Key Highlights

  • Published market data on November 4, 2026 showed Nurix Therapeutics (NASDAQ:NRIX) at USD 15.29, down 40.80%, with a market cap of about USD 1.67 billion and Volume of 5.74 million shares.
  • Nurix Therapeutics (NASDAQ:NRIX) received a USD 700 million upfront payment from Roche for its bexobrutideg collaboration, and reported USD 1.1 billion of cash and marketable securities.
  • Revenue for the quarter ended August 31, 2026 was USD 673.1 million, including USD 653.2 million of Roche license revenue, and Net Income was USD 549.8 million, or USD 4.73 per diluted share.
  • The company said its cash supports operations into the second half of 2029, and the first patient has been dosed in the Phase 3 DAYBreak CLL-306 trial.

What the Company Last Reported

The company reported fiscal third quarter results on October 12, 2026 for the quarter ended August 31, 2026. Total Revenue was USD 673.1 million against USD 7.9 million a year earlier, driven by USD 653.2 million of Roche license revenue. Research and Development expense was USD 79.3 million and general and administrative expense was USD 34.4 million, which included one-time transaction costs. Net income was USD 549.8 million, compared with a loss of USD 86.4 million. The Roche collaboration closed after Hart-Scott-Rodino clearance, with development costs split 40% Nurix and 60% Roche and U.S. profits and losses shared equally.

Pipeline and the Biggest Losers Screen

The Phase 3 DAYBreak CLL-306 trial compares bexobrutideg, 600 mg daily, with pirtobrutinib in about 620 patients with relapsed or refractory CLL or SLL, using objective response rate and progression-free survival as dual primary endpoints. Data presented at EHA 2026 showed a median progression-free survival of 22.1 months and an objective response rate of 83.0% in heavily pretreated patients. The company also discontinued development of NX-2127. A biggest losers screen ranks stocks by one-day decline within a market cap band of USD 300 million to USD 2 billion. No company announcement for November 4 was found, so the cause of the drop is unconfirmed.

Risks and Data Caution

A fall of 40.8% with no found news is unusual, and the quoted price and change are screener data that should be rechecked before relying on them. Published market data shows a price to Earnings ratio of 6.61 and trailing EPS of USD 2.31, but those figures are inflated by the one-time Roche payment and say little about the business. Nurix Therapeutics (NASDAQ:NRIX) has no approved product, and its value depends on bexobrutideg trial results and partner funding. At a market cap of USD 1.67 billion against cash of USD 1.1 billion as of August 31, the market was assigning roughly USD 0.6 billion to the pipeline, simple arithmetic that mixes dates. Any cash use since August is not reflected.

Where Things Stand

No confirmed reason for the 40.8% plunge was found, so the honest answer is that it is unexplained. The reported backdrop was strong, with a USD 700 million upfront payment, USD 1.1 billion of cash, a runway into the second half of 2029 and a Phase 3 trial under way. A drop of this size on no found news may point to an event not yet captured or to a data issue. Nurix Therapeutics (NASDAQ:NRIX) investors should check company filings for any November 4 disclosure before drawing conclusions. Until a cause is identified, the move is better treated as a data point to verify than as a signal, because biotech shares can also fall on trading halts, index changes or large holder sales that do not appear in a company release, and none of those has been found here.